Combination effect naringin and pravastatin in lipid profile and glucose in obese rats

dc.creatorRaffoul Orozco, Abdel K.
dc.creatorÁvila González, Ana E.
dc.creatorRodríguez Razón, Christian Martín
dc.creatorGarcía Cobian, Teresa A.
dc.creatorPérez Guerrero, Edsaul E
dc.creatorGarcía Iglesias, Trinidad
dc.creatorRubio Arellano, Edy David
dc.date2022-09-08T18:35:44Z
dc.date2022-09-08T18:35:44Z
dc.date2018-01
dc.date.accessioned2023-07-21T21:45:47Z
dc.date.available2023-07-21T21:45:47Z
dc.identifierRaffoul-Orozco, A.K., Ávila-González, A.E., Rodríguez-Razón, C.M., García-Cobian, T.A., Pérez-Guerrero, E.E., García-Iglesias, T., Rubio-Arellano, E.D. Combination effect naringin and pravastatin in lipid profile and glucose in obese rats. (2018). Life Sciences, 193, pp. 87-92
dc.identifier0024-3205 Print
dc.identifier1879-0631 Online
dc.identifierDOI: 10.1016/j.lfs.2017.11.044
dc.identifierhttp://repositorio.cualtos.udg.mx:8080/jspui/handle/123456789/1406
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7752877
dc.descriptionArtículo
dc.descriptionAims The purpose of this study was to compare the effect of naringin 100 mg/kg in combination with pravastatin 10 mg/kg by gavage for 6 weeks compared with monotherapy over lipid profiles, glucose levels and weight in murine model of obesity. Main methods The study design was planned with 5 groups of 6 male Wistar Albina rats: Group 1: control with balanced food and vehicle (C −); Group 2: control with Obesity and vehicle (C +); Group 3: Obesity + naringin (N); Group 4: Obesity + pravastatin (P); Group 5: Obesity + pravastatin + naringin (NP). Obesity was developed with a food model. Key findings The naringin groups showed a decrease in weight gain and low glucose values compared to the control group (weight NP:311.4 vs C +:348.6; glucose NP: 173.12 vs C +:235.56) (p < 0.05); the group with naringin + pravastatin combination showed the total cholesterol (TC), LDL and triglycerides (TGs) to normal levels (TC NP:51.6 vs C +:83.4; LDL NP:9.32 vs C +:32.32; TGs NP:39.4 vs C +:89.4) (p < 0.05); but was not statistically significant compared with monotherapy. Significance The combination of naringin and pravastatin did not appear to be better than monotherapy on lipids, but its use could generate euglycemic and antiobesogenic effects, in addition to diminishing the adverse hepatic effects of pravastatin in rats
dc.languageen
dc.publisherElsevier - Science Direct
dc.relationLife Sciences;Volume 193, Pages 87 - 92
dc.subjectDM2
dc.subjectdyslipidemia
dc.subjectnaringin
dc.subjectobesity
dc.subjectphytopharmaceuticals
dc.subjectpravastatin
dc.titleCombination effect naringin and pravastatin in lipid profile and glucose in obese rats
dc.typeArticle


Este ítem pertenece a la siguiente institución